Same sibling marrow following cord allogeneic transplantation as therapy for second relapse acute promyelocytic leukemia in a pediatric patient

Satiro N. De Oliveira; Roy L. Kao; Andrew Pham; Lamarr Taylor Smith; Pamela Kempert; Theodore B. Moore

doi:10.1111/petr.12677

Same sibling marrow following cord allogeneic transplantation as therapy for second relapse acute promyelocytic leukemia in a pediatric patient

Satiro N. De Oliveira, Roy L. Kao, Andrew Pham, Lamarr Taylor Smith, Pamela Kempert, Theodore B. Moore

Research output: Contribution to journal › Article › peer-review

Abstract

Optimal therapy for relapsed APL in pediatric patients is controversial. Allogeneic HSCT is an alternative, with event-free survival of 70-75%. We report a pediatric patient with APL who relapsed 28 months after CBT from her sibling and then was treated with BMT from the same donor. Bone marrow was selected for higher cell dose, donor availability, and partial donor chimerism. Persistent molecular remission was achieved, currently at 65 months after BMT. This case suggests the potential role of GVL activity in APL and illustrates the use of different cell sources from the same donor in allogeneic transplantation for pediatric patients.

Original language	English (US)
Pages (from-to)	337-341
Number of pages	5
Journal	Pediatric transplantation
Volume	20
Issue number	2
DOIs	https://doi.org/10.1111/petr.12677
State	Published - Mar 1 2016
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Keywords

acute promyelocytic leukemia
bone marrow transplant
graft-versus-leukemia
umbilical cord blood

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1111/petr.12677

https://escholarship.org/uc/item/6v5233ww

OpenUrl availability

Full text

Cite this

@article{8f8b1448d50246c4ae1f62c0484dda66,

title = "Same sibling marrow following cord allogeneic transplantation as therapy for second relapse acute promyelocytic leukemia in a pediatric patient",

abstract = "Optimal therapy for relapsed APL in pediatric patients is controversial. Allogeneic HSCT is an alternative, with event-free survival of 70-75%. We report a pediatric patient with APL who relapsed 28 months after CBT from her sibling and then was treated with BMT from the same donor. Bone marrow was selected for higher cell dose, donor availability, and partial donor chimerism. Persistent molecular remission was achieved, currently at 65 months after BMT. This case suggests the potential role of GVL activity in APL and illustrates the use of different cell sources from the same donor in allogeneic transplantation for pediatric patients.",

keywords = "acute promyelocytic leukemia, bone marrow transplant, graft-versus-leukemia, umbilical cord blood",

author = "{De Oliveira}, {Satiro N.} and Kao, {Roy L.} and Andrew Pham and Smith, {Lamarr Taylor} and Pamela Kempert and Moore, {Theodore B.}",

note = "Publisher Copyright: {\textcopyright} 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.",

year = "2016",

month = mar,

day = "1",

doi = "10.1111/petr.12677",

language = "English (US)",

volume = "20",

pages = "337--341",

journal = "Pediatric transplantation",

issn = "1397-3142",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - Same sibling marrow following cord allogeneic transplantation as therapy for second relapse acute promyelocytic leukemia in a pediatric patient

AU - De Oliveira, Satiro N.

AU - Kao, Roy L.

AU - Pham, Andrew

AU - Smith, Lamarr Taylor

AU - Kempert, Pamela

AU - Moore, Theodore B.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Optimal therapy for relapsed APL in pediatric patients is controversial. Allogeneic HSCT is an alternative, with event-free survival of 70-75%. We report a pediatric patient with APL who relapsed 28 months after CBT from her sibling and then was treated with BMT from the same donor. Bone marrow was selected for higher cell dose, donor availability, and partial donor chimerism. Persistent molecular remission was achieved, currently at 65 months after BMT. This case suggests the potential role of GVL activity in APL and illustrates the use of different cell sources from the same donor in allogeneic transplantation for pediatric patients.

AB - Optimal therapy for relapsed APL in pediatric patients is controversial. Allogeneic HSCT is an alternative, with event-free survival of 70-75%. We report a pediatric patient with APL who relapsed 28 months after CBT from her sibling and then was treated with BMT from the same donor. Bone marrow was selected for higher cell dose, donor availability, and partial donor chimerism. Persistent molecular remission was achieved, currently at 65 months after BMT. This case suggests the potential role of GVL activity in APL and illustrates the use of different cell sources from the same donor in allogeneic transplantation for pediatric patients.

KW - acute promyelocytic leukemia

KW - bone marrow transplant

KW - graft-versus-leukemia

KW - umbilical cord blood

UR - http://www.scopus.com/inward/record.url?scp=84959336956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959336956&partnerID=8YFLogxK

U2 - 10.1111/petr.12677

DO - 10.1111/petr.12677

M3 - Article

C2 - 26849401

AN - SCOPUS:84959336956

SN - 1397-3142

VL - 20

SP - 337

EP - 341

JO - Pediatric transplantation

JF - Pediatric transplantation

IS - 2

ER -

Same sibling marrow following cord allogeneic transplantation as therapy for second relapse acute promyelocytic leukemia in a pediatric patient

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this